WP5: Identification of biomarkers sensitive to disease progression (Clinical studies)
Work Packages
Main Objectives
- To characterise the relationship between an integrated biomarker platform and cognitive performance to identify biomarker ‘handprint(s)’ (MATRIX) sensitive to disease progression from MCI to AD.
- To test the prognostic value of the biomarker ‘handprint(s)’ (MATRIX) for stratification and/or enrichment of MCI patients for future clinical trials
- To assess the value of functional decline (natural course of disease) detected by the biomarker ‘handprint’ (MATRIX) as primary clinical endpoints, as compared to standard cognitive assessments.
- To define study design requirements for future evaluation of the therapeutic potential of disease modifying agents in the MCI population
WP Leads
Academic Lead: Pr Giovanni Frisoni (IRCCS-FBF, Italy)
Industry lead: Dr Olivier Blin (GSK)
WP Partners
|
Patient enrolling centres |
Biotechs |
Other |
|
UnivMed, France |
AlzProtect |
AstraZeneca |
|
University of Lille, France |
Exonhit |
GSK |
|
University of Leipzig, Germany |
ICDD |
Novartis |
|
University of Essen, Germany |
Innovative Health Diagnostic |
Roche |
|
Aristotle University of Thessaloniki, Greece |
Qualissima |
MN institute, Italy |
|
VU University, Amsterdam, The Netherlands |
University of Foggia, Italy |
|
|
IRCCS-FBF, Italy |
||
|
IRCCS-SDN, Italy |
||
|
University of Genoa, Italy |
||
|
University of Perugia, Italy |
||
|
UCSC, Italy |
||
|
IDIBAPS, Spain |
Patient enrolment update
|
Month |
Expected |
Enroled |
|
January 2013 |
150 |
54 |
Last Updated: vendredi 01 février 2013
